Bufo melanostictus venom, the Asian common toad or black-spined toad, is not venomous in the traditional sense but is highly poisonous. Its toxic secretions are a complex chemical defense against predation, posing a significant risk to domestic animals and potentially to humans through ingestion or mucous membrane contact. It is not a biting threat.
Key Specifications & Components:
-
Primary Toxins: The major toxic agents are bufadienolides, cardiac glycosides similar to digitalis, which inhibit the Na⁺/K⁺-ATPase pump. The parotoid glands and skin also contain biogenic amines (e.g., serotonin, bufotenin) and catecholamines.
-
Mechanism & Clinical Effects:
-
Cardiotoxicity: Bufadienolides cause profound cardiovascular effects, including severe bradycardia, heart block, ventricular arrhythmias, and potentially fatal cardiac arrest.
-
Neurological Effects: Bufotenin is a hallucinogenic tryptamine, and serotonin contributes to initial hypersalivation, ataxia, and seizures in poisoned animals.
-
Local Irritation: Secretions cause intense irritation to the eyes, nose, and mouth, leading to pain, redness, and excessive salivation.
-
-
Potency & Yield: Toxicity is highly variable but can be severe. The LD₅₀ in mice (intravenous for purified bufotoxin) is approximately 0.3 mg/kg. A single large toad can contain enough toxin to kill a medium-sized dog. No standardized “yield” exists as with snake venom, as secretions are exuded, not injected.
-
Treatment: There is no specific antivenom. Management is decontamination (flush affected areas) and aggressive supportive care. For cardiac glycoside poisoning, treatment may involve administering Digoxin-specific Antibody Fragments (Digibind), along with anti-arrhythmics and electrolyte management. Prevention of exposure is paramount.
